Dallah Healthcare Company (4004) Fair Value & Analysis
Healthcare · SA · Market cap 10.6B SAR
Fair value as of: Jul 31, 2026
From 16 valuation models · updated today
Share price −4.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 97.84 SAR – 154.79 SAR · fair‑value band 67.78 SAR – 112.97 SAR · the 105.20 SAR price screens above the 90.38 SAR fair value. As of Jul 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dallah Healthcare Company (4004) currently trades at 105.20 SAR, while our model-based Fair Value estimate is 90.38 SAR, implying the stock looks roughly 14.1% overvalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Dallah Healthcare Company generated revenue of 4.2B SAR at a net margin of 11.0%. Revenue grew 21.7% year over year. It earns a return on equity of 11.1%. Net debt stands at 3.7B SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 67.78 SAR (bear case) to 112.97 SAR (bull case); at 105.20 SAR, the current price sits within that range. The share trades about 32% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -14%, 4004 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Dallah Healthcare Company operates as a health care company in the Kingdom of Saudi Arabia. The company engages in operating, managing, equipping, and developing hospitals and healthcare facilities, medical centres, complexes, and clinics; and the provision of manpower and support services.
Full company description
Dallah Healthcare Company operates as a health care company in the Kingdom of Saudi Arabia. The company engages in operating, managing, equipping, and developing hospitals and healthcare facilities, medical centres, complexes, and clinics; and the provision of manpower and support services. It also offers pharmaceuticals, cosmetics, consumables, equipment, and nutritional supplements, as well as medications, diagnostics, and medical technologies. In addition, the company provides personalized treatment plans, post-surgical recovery and chronic condition management, in-home nursing and physiotherapy, and teleconsultations and remote monitoring services. Further, it manages private hospitals, medical and diagnostic centers, and an analytical laboratory; and provides medical services. The company was formerly known as Dallah Healthcare Holding Company and changed its name to Dallah Healthcare Company in November 2016. The company was founded in 1987 and is based in Riyadh, Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Dallah Healthcare Company reported revenue of 4.1B SAR in FY2025 versus 2.1B SAR in FY2021, a compound +17.9%/yr. Reported net income was 538M SAR in FY2025, compounding +20.1%/yr from FY2021.
Is 4004 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FRE | €39.90 | €31.98 | -20% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $164.77 | $280.85 | +70% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
| DaVita Inc DVAI34 | R$1,170 | R$210.54 | -82% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,469 | ₹2,967 | -65% |
| Fresenius Medical Care AG FMSC34 | R$112.00 | R$164.58 | +47% |
| Aier Eye Hospital Group 300015 | ¥8.49 | ¥10.83 | +28% |
Compare Dallah Healthcare Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dallah Healthcare Company (4004) overvalued or undervalued?
What is the fair value of 4004?
What is the quality score of 4004?
What is the revenue of Dallah Healthcare Company (4004)?
What is the net profit margin of 4004?
Does Dallah Healthcare Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Dallah Healthcare Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.